Thursday, July 9, 2026

biotech · Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · CUE

Cue Biopharma

Cue Biopharma is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker CUE. Primary therapeutic focus areas include Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal

Boston, USA HQ
2014 Founded
37 Employees
Public company Type
CUE · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2014
Employees
37
Programs
5
Drugs
0
Patents
30

Quick answer

Cue Biopharma is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker CUE. Primary therapeutic focus areas include Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Colorectal Cancer, Recurrent Glioblastoma. NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 30 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (3), phase 2 (2).

Company snapshot

Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune

  • 5 active pipeline program(s) linked via ClinicalTrials.gov.
  • 30 US patent(s) indexed to this assignee profile.
  • 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cue Biopharma. Not investment advice.

Top assets

Lead pipeline drugs

  • CUE-101 Head and Neck Squamous Cell Carcinoma
    Phase 2
  • CUE-101 Oropharyngeal Squamous Cell Carcinoma
    Phase 2
  • CUE-101 Head and Neck Cancer
    Phase 1
  • CUE-102 Colorectal Cancer
    Phase 1

Active clinical programs

  • CUE-101 Head and Neck Squamous Cell Carcinoma
    Phase 2
  • CUE-101 Oropharyngeal Squamous Cell Carcinoma
    Phase 2
  • CUE-101 Head and Neck Cancer
    Phase 1
  • CUE-102 Colorectal Cancer
    Phase 1

Momentum

Proprietary activity score for Cue Biopharma.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 5 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Cue Biopharma.

  1. Clinical update

    CUE-101 — Phase 2

  2. Clinical update

    CUE-101 — Phase 2

  3. Clinical update

    CUE-101 — Phase 1

  4. Clinical update

    CUE-102 — Phase 1

  5. Clinical update

    CUE-102 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Cue Biopharma?

    Cue Biopharma is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker CUE. Primary therapeutic focus areas include Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Colorectal Cancer, Recurrent Gliob

  • Is Cue Biopharma publicly traded?

    Yes. Cue Biopharma is listed with ticker CUE on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Cue Biopharma develop or market?

    No drug profiles are currently linked to Cue Biopharma. Pipeline programs may still list investigational assets.

  • What are the latest developments for Cue Biopharma?

    In the last 12 months our linked public records show 5 trial program update(s) and 1 US patent grant(s) tied to this profile.

  • What therapeutic areas does Cue Biopharma focus on?

    Cue Biopharma focuses on Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
6
Oncology
4